NASDAQ:AGRX - Agile Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Agile Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.99 -0.01 (-0.50 %) (As of 12/12/2019 01:55 AM ET) Add Compare Today's Range$1.95Now: $1.99▼$2.0350-Day Range$0.37MA: $1.72▼$2.3852-Week Range$0.35Now: $1.99▼$2.97Volume875,174 shsAverage Volume1.74 million shsMarket Capitalization$118.01 millionP/E RatioN/ADividend YieldN/ABeta0.69 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGRX Previous Symbol CUSIPN/A CIK1261249 Webhttp://www.agiletherapeutics.com/ Phone609-683-1880Debt Debt-to-Equity RatioN/A Current Ratio10.39 Quick Ratio10.39Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.59 per share Price / Book3.37Profitability EPS (Most Recent Fiscal Year)($0.58) Net Income$-19,780,000.00 Net MarginsN/A Return on Equity-65.71% Return on Assets-61.13%Miscellaneous Employees13 Outstanding Shares59,302,000Market Cap$118.01 million Next Earnings Date3/10/2020 (Estimated) OptionableOptionable Receive AGRX News and Ratings via Email Sign-up to receive the latest news and ratings for AGRX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:AGRX Rates by TradingView Agile Therapeutics (NASDAQ:AGRX) Frequently Asked Questions What is Agile Therapeutics' stock symbol? Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX." How were Agile Therapeutics' earnings last quarter? Agile Therapeutics Inc (NASDAQ:AGRX) announced its quarterly earnings data on Monday, October, 28th. The specialty pharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.00. View Agile Therapeutics' Earnings History. When is Agile Therapeutics' next earnings date? Agile Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Agile Therapeutics. What price target have analysts set for AGRX? 6 brokerages have issued 12-month target prices for Agile Therapeutics' shares. Their forecasts range from $3.00 to $5.00. On average, they anticipate Agile Therapeutics' share price to reach $4.20 in the next twelve months. This suggests a possible upside of 111.1% from the stock's current price. View Analyst Price Targets for Agile Therapeutics. What is the consensus analysts' recommendation for Agile Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agile Therapeutics. What are Wall Street analysts saying about Agile Therapeutics stock? Here are some recent quotes from research analysts about Agile Therapeutics stock: 1. According to Zacks Investment Research, "Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey. " (10/30/2019) 2. Maxim Group analysts commented, "Agile Therapeutics announced that the NDA for Twirla (low-dose contraceptive patch) has been resubmitted to the FDA. FDA has 30 days to accept; review period expected to be 6 months." (5/17/2019) 3. HC Wainwright analysts commented, "We don’t think this should even be required, as Twirla is a different product than Xulane/Ortho Evra, not a generic copy, so its benefit-risk profile—which we think is better—should stand on its own merits. Nevertheless, the minutes were consistent with our expectation for a straightforward two-week crossover study (one week on each patch) to show that Twirla adhesion is non-inferior (NI) to Xulane. The company has not disclosed the specific NI margin that the agency is requiring, but the planned sample size of only n=80 suggests to us that the FDA has given them some NI breathing room. We are confident in success based on Phase 3 adhesion data (more below). Agile already had the study teed up and ready to go, and has immediately initiated it with a dermatology-specialized CRO, TKL Research." (1/11/2019) Has Agile Therapeutics been receiving favorable news coverage? News articles about AGRX stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Agile Therapeutics earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave news coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Agile Therapeutics. Who are some of Agile Therapeutics' key competitors? Some companies that are related to Agile Therapeutics include MacroGenics (MGNX), Ardelyx (ARDX), Akorn (AKRX), Catalyst Pharmaceuticals (CPRX), Organogenesis (ORGO), Sinovac Biotech (SVA), ProQR Therapeutics (PRQR), DiaMedica Therapeutics (DMCAF), Aptorum Group (APM), Progenics Pharmaceuticals (PGNX), BioSpecifics Technologies (BSTC), Assembly Biosciences (ASMB), Molecular Templates (MTEM), Stealth BioTherapeutics (MITO) and AnaptysBio (ANAB). What other stocks do shareholders of Agile Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include Opko Health (OPK), AcelRx Pharmaceuticals (ACRX), SCYNEXIS (SCYX), TherapeuticsMD (TXMD), Amarin (AMRN), Novavax (NVAX), Sorrento Therapeutics (SRNE), Trevena (TRVN), Viking Therapeutics (VKTX) and Adamis Pharmaceuticals (ADMP). Who are Agile Therapeutics' key executives? Agile Therapeutics' management team includes the folowing people: Mr. Alfred F. Altomari, Chairman & CEO (Age 60)Mr. Scott M. Coiante, CFO & Sr. VP (Age 52)Dr. Elizabeth Ijeoma Onyemelukwe Garner, Sr. VP & Chief Medical Officer (Age 51)Mr. Geoffrey P. Gilmore, Gen. Counsel (Age 53)Mr. Robert G. Conway, Sr. VP of Enterprise Planning & Information Management (Age 62) Who are Agile Therapeutics' major shareholders? Agile Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Millennium Management LLC (0.25%) and Squarepoint Ops LLC (0.08%). Company insiders that own Agile Therapeutics stock include Abhijeet J Lele, Alfred Altomari, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Institutional Ownership Trends for Agile Therapeutics. Which major investors are buying Agile Therapeutics stock? AGRX stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC and Squarepoint Ops LLC. Company insiders that have bought Agile Therapeutics stock in the last two years include Abhijeet J Lele, Alfred Altomari and Perceptive Advisors Llc. View Insider Buying and Selling for Agile Therapeutics. How do I buy shares of Agile Therapeutics? Shares of AGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Agile Therapeutics' stock price today? One share of AGRX stock can currently be purchased for approximately $1.99. How big of a company is Agile Therapeutics? Agile Therapeutics has a market capitalization of $118.01 million. The specialty pharmaceutical company earns $-19,780,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Agile Therapeutics employs 13 workers across the globe.View Additional Information About Agile Therapeutics. What is Agile Therapeutics' official website? The official website for Agile Therapeutics is http://www.agiletherapeutics.com/. How can I contact Agile Therapeutics? Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The specialty pharmaceutical company can be reached via phone at 609-683-1880 or via email at [email protected] MarketBeat Community Rating for Agile Therapeutics (NASDAQ AGRX)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 367 (Vote Outperform)Underperform Votes: 224 (Vote Underperform)Total Votes: 591MarketBeat's community ratings are surveys of what our community members think about Agile Therapeutics and other stocks. Vote "Outperform" if you believe AGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/12/2019 by MarketBeat.com StaffFeatured Article: How Do Front-End Loads Impact an Investment?
